Novo Nordisk Reports Strong Real-World Outcomes With Semaglutide 2 mg Escalation

Novo Nordisk has reported new real-world evidence showing that adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg achieved glycemic outcomes comparable to patients who switched to tirzepatide and were more likely to achieve clinically meaningful weight loss. The findings from the COMPETE SWITCH study will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions.

The retrospective cohort study used Komodo Health’s Healthcare Map linked with laboratory data and evaluated treatment intensification strategies between January 2018 and September 2025 among adults with type 2 diabetes receiving semaglutide 1 mg.

Comparable Glycemic Outcomes

The HbA1c cohort included 64,888 adults, with 55,550 patients escalating to semaglutide 2 mg and 9,338 switching to tirzepatide. Baseline HbA1c was 7.2% in both groups.

After one year, 74.7% (95% CI: 73.3%–76.2%) of patients receiving semaglutide 2 mg achieved HbA1c below 7%, compared with 75.1% (95% CI: 74.0%–76.2%) of those who switched to tirzepatide. Over follow-up, patients in both groups were similarly likely to achieve the HbA1c target (estimate 0.98; 95% CI: 0.94–1.02; P=0.343), indicating no significant difference in glycemic control.

Michael Radin, Executive Medical Director at Novo Nordisk Inc., said the findings support ADA treatment goals and suggest that many patients already receiving semaglutide may achieve glycemic and weight-management targets through dose escalation rather than switching therapies.

Weight-Loss Success with Semaglutide Escalation

The weight-loss cohort included 56,852 adults, with 48,596 patients escalating to semaglutide 2 mg and 8,256 switching to tirzepatide. Baseline body weight was 105 kg and 106.2 kg, respectively.

By one year, 60.5% (95% CI: 58.7%–62.3%) of patients receiving semaglutide 2 mg achieved at least 5% weight loss versus 55.3% (95% CI: 53.9%–56.7%) among those who switched to tirzepatide. Semaglutide escalation was also associated with a significantly greater likelihood of achieving at least 5% weight loss over time (HR 1.19; 95% CI: 1.15–1.24; P<0.001).

Tirzepatide Titration Patterns and Clinical Implications

Among patients who switched to tirzepatide, approximately 24% of the HbA1c cohort and 40% of the weight-loss cohort escalated beyond 5 mg, while only 3%–5% reached the maximum 15 mg dose. These findings provide important context for interpreting comparative outcomes in routine clinical practice.

Kathryn S. Tierney, MSN, APRN, FNP-BC, of Middlesex Health MultiSpecialty Group, said many patients already established on semaglutide may prefer intensifying existing therapy rather than transitioning to a new medication when treatment goals can be achieved with meaningful glycemic and weight-loss benefits.

Study Limitations

As an observational claims analysis, COMPETE SWITCH cannot establish causality and may be affected by residual confounding. The database may underrepresent patients with intermittent coverage or underserved populations, and social determinants of health and adherence factors could not be fully assessed. Nevertheless, the study provides large-scale real-world evidence supporting semaglutide dose escalation as a clinically relevant treatment strategy for adults with type 2 diabetes.

Reference

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data